Expert Perspectives on CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer

Expert Perspectives on CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer

Thursday, January 31, 2019 in Rockford, IL
Live Meeting -- Swedish American Regional Cancer Center, 4:00 PM CT
Conference Rooms 1, 2, 3

Agenda

  • Background on hormone receptor–positive, HER2-negative advanced breast cancer
  • The growing role of CDK4/6 inhibitors in treating hormone receptor–positive advanced breast cancer
    • Critical review of key clinical trials data: palbociclib, ribociclib, abemaciclib
    • Practical application in the clinic: CDK4/6 inhibition and endocrine partner
  • Clinical management of potential toxicities and drug interactions related to CDK4/6 inhibitors in breast cancer
  • Emerging data, ongoing clinical trials, and future directions
    • Acquired resistance to CDK4/6 inhibitors
    • Moving CDK4/6 inhibition into earlier settings
    • Biomarkers for CDK4/6 response

Faculty

Faculty
Kari Wisinski, MD

Associate Professor of Medicine
Co-Leader
, UWCCC Breast Cancer Oriented Team
University of Wisconsin Carbone Cancer Center
Associate Professor
Division of Hematology and Medical Oncology
Department of Medicine
University of Wisconsin Hospital and Clinics
Madison, Wisconsin

Goal Statement
The goal of this activity is to improve participants’ performance in using CDK4/6 inhibitors to improve outcomes for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Target Audience 
This program is intended for medical oncologists, the multidisciplinary team, and associated healthcare providers who care for patients with breast cancer.

Learning Objectives 

  • Discuss the rationale for targeting CDK4/6 in breast cancer
  • Evaluate available clinical data on abemaciclib, palbociclib, and ribociclib and their applications to current treatment algorithms for patients with de novo or recurrent metastatic hormone receptor–positive, HER2-negative breast cancer
  • Describe current therapeutic strategies and ongoing clinical trials of CDK4/6 inhibitors for hormone receptor–positive, HER2-negative breast cancer
  • Explain similarities and differences among the CDK4/6 inhibitors
  • Summarize mechanisms of acquired resistance to CDK4/6 inhibitors and current treatment options after disease progression on CDK4/6 inhibitor–based therapy
  • Identify potential biomarkers of sensitivity to CDK4/6 inhibitors
  • Manage toxicities specific to CDK4/6 inhibitors

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.